Predictors of progression-free survival and local tumor control after percutaneous thermal ablation of oligometastatic breast cancer: Retrospective study Journal Article

  

Authors:	Ridouani, F.; Solomon, S. B.; Bryce, Y.; Bromberg, J. F.; Sofocleous, C. T.; Deipolyi, A. R.
Article Title:	Predictors of progression-free survival and local tumor control after percutaneous thermal ablation of oligometastatic breast cancer: Retrospective study
Abstract:	Purpose: To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). Materials and Methods: A total of 33 women (mean age 52 ± 12 years old; range, 28–69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6–50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT. Results: Median PFS was 10 months (95% confidence interval [CI], 6.2 –14.5 months), and time to local progression was 11 months (95% CI, 5–16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P =.037) and younger patients (12 vs 4 months; P =.039) treated to eradicate all sites of disease (13 vs 5 months; P =.05). Eighteen patients (55%) developed new metastases during study follow-up. Conclusions: Thermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated. © 2020 SIR
Keywords:	adult; clinical article; treatment response; aged; overall survival; cancer recurrence; systemic therapy; bone metastasis; nuclear magnetic resonance imaging; follow up; progression free survival; computer assisted tomography; bleeding; retrospective study; age; liver metastasis; lung metastasis; minimal residual disease; pneumothorax; contrast enhancement; liver resection; tumor growth; cancer control; cryoablation; radiofrequency ablation; metastatic breast cancer; video assisted thoracoscopic surgery; hematocrit; fluoroscopy; hemoptysis; soft tissue metastasis; tumor ablation; survival prediction; arterial embolization; cancer prognosis; estrogen receptor positive breast cancer; human epidermal growth factor receptor 2 positive breast cancer; human; female; priority journal; article; anatomic landmark; median survival time; estrogen receptor negative breast cancer; positron emission tomography-computed tomography; breast cancer molecular subtype; progesterone receptor positive breast cancer; microwave thermotherapy; progesterone receptor negative breast cancer; human epidermal growth factor receptor 2 negative breast cancer
Journal Title:	Journal of Vascular and Interventional Radiology
Volume:	31
Issue:	8
ISSN:	1051-0443
Publisher:	Elsevier Science, Inc.
Date Published:	2020-08-01
Start Page:	1201
End Page:	1209
Language:	English
DOI:	10.1016/j.jvir.2020.02.016
PUBMED:	32698956
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088106365&doi=10.1016%2fj.jvir.2020.02.016&partnerID=40&md5=3aab29b6df861703d0ee1bacc1eb93a7
Notes:	Article -- Export Date: 1 September 2020 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/169995